NASDAQ OMX

Medibio Appoints Mental Healthcare Advocate and Former Congressman, Patrick Kennedy, to Board of Directors

5.7.2017 15:00 | NASDAQ OMX

Del

SYDNEY, Australia and MINNEAPOLIS, July 05, 2017 (GLOBE NEWSWIRE) -- Australian Stock Exchange listed medical technology company Medibio Limited (MEB or the Company) is pleased to announce the appointment of The Honourable Patrick J. Kennedy to the Board of Directors.

Patrick J. Kennedy is a former member of the U.S. House of Representatives (D-R.I.) and the nation's leading political voice on mental illness, addiction, and other brain diseases.  During his 16-year career representing Rhode Island in Congress, he fought a national battle to end medical and societal discrimination against these illnesses, highlighted by his lead sponsorship of the Mental Health Parity and Addiction Equity Act of 2008.  As a chief sponsor of one of the major pieces of legislation of 2008, the Mental Health Parity Act, a bill requiring most group health plans to provide coverage for the treatment of mental illnesses that is comparable to what they provide for physical illnesses. Mr. Kennedy was also recently appointed to President Trump's Commission on Combating Drug Addiction and the Opioid Crisis.  His political career and his brave openness about his own health challenges provide unique expertise to Medibio.

"Medibio's technology is truly groundbreaking, and has the potential to fundamentally change the mental health system for the better. That's why I am proud to be part of this team," said Kennedy. "This is a company that is truly on the cutting edge, and their diagnostic and analytic tools will give clinicians the power to treat patients more effectively, using better data, and with a focus on better outcomes."

Medibio Managing Director and CEO, Jack Cosentino, said, "Patrick is a significant addition to the Medibio Board! His wealth of experience gained from serving in the U.S. Congress along with his advocacy for Mental Health will open doors and heighten awareness for Medibio's technology.  He has proved successful in tackling Mental Health as one of the greatest challenges in healthcare today.  His knowledge, both through personal experience and legislative accomplishments, will help guide us in laying the strategic foundations for large-scale operations and the necessary payment and reimbursement coverage of our innovative, new technology. We welcome Patrick to the board of Medibio and value his leadership and passion to serve people with mental health conditions."

Following his 8th term serving in the U.S. Congress, Kennedy has become a leading advocate for increased Mental Health & Addiction treatment coverage in the United States.  He is a co-founder of One Mind for Research, which seeks to increase resources and collaboration in brain research and founder of the Kennedy Forum which advances a roadmap to transform mental health and addiction care.

Mr. Kennedy served three terms in the Rhode Island State legislature before he was elected as a Democratic member of the United States House of Representatives from 1995 to 2011.  Kennedy served on the Armed Services Committee and the Appropriations committee, where he served on the subcommittee on Veterans Affairs and the Subcommittee on Labor, Health and Human Services, Education, and the NIH. While in Congress, he was a vocal advocate for healthcare reform and the chief sponsor of the 2008 Mental Health Parity and Addiction Equity Act.

Medibio Board Chair Chris Indermaur said, "Mr. Kennedy is a true win for Medibio.  His vast experience and credentials both with the government as well as his current appointment serving on the White House commission will align well with the challenges affecting those struggling with addiction and mental illness.  We are pleased to have him join our esteemed board."

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF), headquartered in Melbourne, Australia, with US headquarters in Minneapolis, Minnesota, is an evidence-based medical technology company that has developed an objective test to assist in the diagnosis and management of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes a panel of patented (and patent pending) circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental state.  Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Medibio is listed on the Australian Securities Exchange and trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com and www.asx.com.au.

To learn more about Medibio visit www.Medibio.com.au.

Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director
Medibio Limited
jack.cosentino@medibio.com.au
T: +1 (952) 465 4787
Australian Media Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs24.7.2017 22:05Pressemelding

Phase 2 data in older adults (E205) demonstrate adjuvants and 2-dose regimens significantly increase the magnitude, duration and quality of the RSV F Vaccine immune response   New data demonstrate that Novavax' construct is a stable prefusogenic RSV F antigen, distinctive from other candidates, that elicits potent neutralizing antibody responses to multiple key epitopes    Path forward for a Phase 2 efficacy trial in 2018 based on signal in COPD population identified in prior older adult clinical trials    Phase 3 Prepare(TM) trial accelerating and now includes 80 sites across 11 countries allowing continuous enrollment across global seasons       GAITHERSBURG, Md., July 24, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced positive topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, new preclinical data on its RSV F Vaccin

Announcing the First U.S. Federally Regulated Exchange and Clearing House for Digital Currency Derivatives24.7.2017 21:51Pressemelding

LedgerX Receives U.S. Federal Government License to Trade, Clear and Settle Digital Currency Contracts  NEW YORK, July 24, 2017 (GLOBE NEWSWIRE) -- LedgerX, the New York-based institutional trading and clearing platform for digital currencies, receives approval to operate the first U.S. federally-regulated exchange and clearing house for derivatives contracts settling in digital currencies.   A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/eafba6f5-a1ce-47da-81a0-0aaacfe7caef See Related Release:  The U.S. Commodity Futures Trading Commission (CFTC) grants LedgerX LLC a Derivatives Clearing Organization license (DCO) to clear and physically settle digital currency-based financial instruments.   LedgerX will be the first federally supervised options venue for bitcoin Participants in the Le

Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer24.7.2017 15:00Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Richard Wenstrup, MD, as Chief Medical Officer. Dr. Wenstrup brings to Oxford Immunotec more than 20 years of clinical leadership experience, including over a decade within the diagnostics industry. Most recently, Dr. Wenstrup served as Executive Vice President, Chief Medical Officer, for Myriad Genetics, Inc., where he played a key leadership role and made substantial contributions across the company that helped drive and support a multi-fold increase in revenue over a decade. In addition to building and leading Myriad's clinical and medical affairs teams, Dr. Wenstrup was actively involved in the company's product development, M&A, and in-licensing activi

Minerva Neurosciences Announces Departure of Directors24.7.2017 14:30Pressemelding

WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen.  Following the Company's recent public offering and the resultant improvement in its financial position, Dr. Ollier and Mr. Vandervelpen will step down to focus on their private equity activities. Their resignations are effective today. "We would like to thank Michele and Nico for their invaluable contributions to Minerva as a private company and as it has transitioned during the past three years from a venture capital-backed company to a publicly traded company that has advanced several assets into late-stage clinical development," said Marc Beer, chairman of Minerva. About Minerva Neurosciences

French Energy Operator GRDF Enlists Appian's Low-code Platform for Enterprise-wide Deployment24.7.2017 14:00Pressemelding

RESTON, Va., July 24, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announces that leading French gas distributor GRDF will deploy its latest enterprise application developed on Appian's low-code platform. The new application is designed to manage the extension of gas distribution networks in France, and will be deployed to more than 2,500 users across GRDF. This marks GRDF's fifth major application deployed on the Appian Platform.  GRDF is already benefitting from Appian's low-code applications, which enhance the customer experience and transform traditional business methods to more efficient and agile processes. Appian provides GRDF with the speed needed to capitalize on opportunities that the digital world presents, as well as the power to streamline complex business processes. Jean-Marc Wojtecki, Deputy CIO at GRDF, commented: "We solidly believe in the power of low-code for building new applications quickly. Appian allows us to innovate more effici

Placetel is named as a leading UC solution in Germany by ISG Experton Group24.7.2017 10:00Pressemelding

Placetel, Powered by BroadSoft, named as a leader in the "ISG Provider Lens Germany 2017 - Cloud Transformation / Operation Services & XaaS" Study recognizes broad functional spectrum and strong focus on SMEs Operation of data centers in Germany is acknowledged as a further advantage COLOGNE, Germany, July 24, 2017 (GLOBE NEWSWIRE) --  Placetel, a cloud PBX service from BroadSoft Germany GmbH, has been named by ISG/Experton Group, a leading fully integrated research, advisory and consulting company, as one of the best cloud-based solutions for Unified Communications as a Service (UCaaS) in Germany. ISG/Experton Group positioned Placetel, powered by BroadSoft, in the leadership quadrant in its provider comparison "ISG Provider Lens Germany 2017 - Cloud Transformation / Operation Services & XaaS". An infographic accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attach

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom